Claris Bio

Executive Summary

Claris Bio is a clinical-stage biotech company based in Cambridge, Massachusetts, dedicated to developing novel biologic therapies for unmet needs in ophthalmology, with an initial focus on corneal diseases. The company's lead program is a topical ocular biologic formulation of desalted Hepatocyte Growth Factor (dHGF) intended to treat Limbal Stem Cell Deficiency (LSCD), a condition characterized by corneal scarring and vision loss due to stem cell depletion. LSCD currently lacks approved pharmacologic treatments, and Claris Bio's approach leverages the regenerative properties of HGF to promote corneal epithelial repair. The company was founded in 2020 and has advanced its dHGF program through preclinical development, positioning it for potential first-in-human studies. By targeting a specific patient population with high unmet need and utilizing a biologic modality with a differentiated mechanism, Claris Bio aims to establish a novel standard of care in corneal regenerative medicine.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for dHGF in LSCD75% success
• Q3 2026Preclinical data presentation at major ophthalmology conference85% success
• TBDPotential partnership or licensing deal for dHGF program30% success